Poor drug penetration is a major problem in cancer therapy. Fibrotic tumor stroma has been considered as one of the central barriers that hamper drug penetration into tumor tissue. Recent data indicate that our tumor penetrating peptide, iRGD, takes advantage of the stroma to penetrate tumor tissue. We have also found that iRGD inhibits metastasis formation, possibly by modifying the tumor microenvironment. This proposal aims to understand the mechanisms of stroma penetration and anti-metastatic activities of iRGD by focusing on carcinoma-associated fibroblasts (CAFs), the most abundant and critical component of tumor stroma. The iRGD peptide (CRGDK/RGPD/EC) contains an RGD tumor specific motif and a CendR motif (R/KXXR/K) that mediates tissue and cell penetration through binding to neuropilin-1 (NRP-1). iRGD triggers a NRP-1- and energy-dependent active bulk transport through tumors that allows compounds to penetrate efficiently into tumor tissue and cells. Therefore, attaching a drug to iRGD or simply co-injecting a drug with iRGD leads to vastly enhanced drug penetration and drug activities in tumor tissue with no enhanced toxicity to normal organs. Our recent data suggest a central role of CAFs in the iRGD tumor penetration activities. Time- dependent tumor homing studies have revealed that iRGD primarily penetrates tumor stroma and then gradually spreads into adjacent tumor cells. During this process, iRGD extensively accumulates into CAFs. In addition to utilizing CAFs as a mediator of tissue penetration, iRGD also appears to affect CAF functions and alter tumor microenvironment. Long-term treatment of tumor mice with iRGD resulted in a dramatic decrease in the number of CAFs in the tumor tissue and a significant inhibition of metastasis. Interestingly, it is becoming evident that the expression of NRP-1, the receptor of iRGD, is critical for activated fibroblast functions. In this application, we propose to study the roles of NRP-1 positive CAFs in the tumor penetration mechanism and the biological activities of iRGD. Mechanistic studies of the iRGD tumor stroma penetration would facilitate the use of the technology in targeting desmoplastic tumors such as pancreatic cancer that are the most therapeutically challenging tumor types in the clinic. Studying iRGD effects on tumor microenvironment modification may lead to the discovery of novel biological functions of iRGD that may serve as a basis of metastasis treatment strategies. Major advances in cancer therapy may ensue.

Public Health Relevance

Mechanistic studies to understand the exceptional tumor tissue and cell penetration of our iRGD peptide will be performed in view of carcinoma-associated fibroblast functions. Novel biological functions of iRGD that modify tumor microenvironment and lead to metastasis inhibition will also be explored. The project may result in a technology that enables targeting of clinically challenging desmoplastic cancers, and a comprehensive anti- cancer strategy that destroys existing tumors and inhibits metastasis simultaneously.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Fu, Yali
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University
Schools of Medicine
New York
United States
Zip Code
Ikemoto, Hideki; Lingasamy, Prakash; Anton Willmore, Anne-Mari et al. (2017) Hyaluronan-binding peptide for targeting peritoneal carcinomatosis. Tumour Biol 39:1010428317701628
Toome, Kadri; Willmore, Anne-Mari A; Paiste, Päärn et al. (2017) Ratiometric in vivo auditioning of targeted silver nanoparticles. Nanoscale 9:10094-10100
Hunt, Hedi; Simón-Gracia, Lorena; Tobi, Allan et al. (2017) Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide-guided pro-apoptotic nanoparticles. J Control Release 260:142-153
Liu, Xiangyou; Braun, Gary B; Qin, Mingde et al. (2017) In vivo cation exchange in quantum dots for tumor-specific imaging. Nat Commun 8:343
Paasonen, Lauri; Sharma, Shweta; Braun, Gary B et al. (2016) New p32/gC1qR Ligands for Targeted Tumor Drug Delivery. Chembiochem 17:570-5
Liu, Xiangyou; Braun, Gary B; Zhong, Haizheng et al. (2016) Tumor-Targeted Multimodal Optical Imaging with Versatile Cadmium-Free Quantum Dots. Adv Funct Mater 26:267-276
Willmore, Anne-Mari A; Simón-Gracia, Lorena; Toome, Kadri et al. (2016) Targeted silver nanoparticles for ratiometric cell phenotyping. Nanoscale 8:9096-101
Simón-Gracia, Lorena; Hunt, Hedi; Scodeller, Pablo et al. (2016) iRGD peptide conjugation potentiates intraperitoneal tumor delivery of paclitaxel with polymersomes. Biomaterials 104:247-57
Braun, Gary B; Sugahara, Kazuki N; Yu, Olivia M et al. (2016) Urokinase-controlled tumor penetrating peptide. J Control Release 232:188-95
Sugahara, Kazuki N; Braun, Gary B; de Mendoza, Tatiana Hurtado et al. (2015) Tumor-penetrating iRGD peptide inhibits metastasis. Mol Cancer Ther 14:120-8

Showing the most recent 10 out of 14 publications